Genomate Health has acquired Oncompass Medicine for an undisclosed amount, marking a significant expansion in the personalized oncology sector. Oncompass Medicine, a health information company, is renowned for its Real-Time Oncology Treatment Calculator, a unique technology designed to assist oncologists and cancer patients in identifying and accessing optimal cancer therapies.
Oncompass's innovative calculator rapidly processes complex data, ranking personalized, targeted therapeutic options within 20 milliseconds. This capability spans 405 cancer types, considers 52,000 mutations, leverages 26,838 medico-biological norms, and evaluates 1,417 medicinal active agents. The company collaborates with oncology centers and molecular diagnostics providers, integrating its advanced decision support into clinical workflows.
This acquisition by Genomate Health underscores a strategic move to enhance its offerings in precision medicine and clinical decision support. By buying Oncompass Medicine, Genomate Health gains proprietary technology that streamlines the complex process of matching patients with the most effective treatments based on their unique genetic profiles and disease characteristics. The integration of Oncompass's robust data analysis and rapid recommendation engine is expected to significantly bolster Genomate Health's capabilities in delivering advanced healthcare solutions.
The synergy between Genomate Health's existing infrastructure and Oncompass's specialized expertise is anticipated to accelerate the adoption of personalized cancer care. The combined entity aims to empower healthcare professionals with more precise tools, ultimately improving patient outcomes by facilitating quicker access to highly targeted therapies. This strategic purchase is set to drive innovation in oncology, making sophisticated treatment guidance more accessible and efficient for the global cancer community.